Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRAINING study of Grafalon for early borderline kidney allograft lesions
2021-003089-11Phase 4Active
- Sponsor
- Fundación Canaria Instituto de Investigación Sanitaria de Canarias
- Start
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of antithymocyte globulin rabbit in kidney allograft rejection and subclinical inflammation (2 arms), sponsored by Fundación Canaria Instituto de Investigación Sanitaria de Canarias. Primary endpoint: Presence of interstitial fibrosis/tubular atrophy. Started Dec 2021; status: active.
02
Drugs
antithymocyte globulin rabbit
03
Conditions
kidney allograft rejectionsubclinical inflammation
Beyond the preview
Go deeper on 2021-003089-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003089-11.